Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
Hans J. Hammers
Research Funding - Bristol-Myers Squibb
Elizabeth R. Plimack
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - Acceleron Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Merck
Jeffrey R. Infante
No relevant relationships to disclose
Marc S. Ernstoff
Research Funding - Bristol-Myers Squibb
Brian I. Rini
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Pfizer
Research Funding - Acceleron Pharma; Bristol-Myers Squibb; GlaxoSmithKline; immatics; Merck; Millennium; Pfizer
David F. McDermott
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Prometheus
Albiruni R. A. Razak
No relevant relationships to disclose
Sumanta Kumar Pal
No relevant relationships to disclose
Martin Henner Voss
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Novartis; Pfizer
Padmanee Sharma
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; Jounce Therapeutics; MedImmune
Stock Ownership - Jounce Therapeutics
Research Funding - Bristol-Myers Squibb
Christian K. Kollmannsberger
No relevant relationships to disclose
Daniel Yick Chin Heng
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Novartis; Pfizer
Jennifer L. Spratlin
No relevant relationships to disclose
Yun Shen
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb (B)
John F. Kurland
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Paul Gagnier
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Asim Amin
Consultant or Advisory Role - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb (I)
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb